Tearsheet

Sangamo Therapeutics (SGMO)

Market Price (9/18/2025): $0.53 | Market Cap: $136.2 Mil
Sector: Health Care | Industry: Biotechnology

Sangamo Therapeutics (SGMO)

Market Price (9/18/2025): $0.53
Market Cap: $136.2 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%	Weak multi-year price returns 2Y Excs Rtn is -99%, 3Y Excs Rtn is -152%	Penny stock Mkt Price is 0.5
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 566%		Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -63 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -77%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -54%		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44%
3			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -53%
4			High stock price volatility Vol 12M is 133%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 566%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -54%
3	Weak multi-year price returns 2Y Excs Rtn is -99%, 3Y Excs Rtn is -152%
4	Penny stock Mkt Price is 0.5
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -63 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -77%
6	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -53%
8	High stock price volatility Vol 12M is 133%

Market Valuation

	9/18/25	2024	2023	2022	2021
Share Price CYE	$0.53	$1.02	$0.54	$3.14	$7.50
Market Cap CYE ($ Mil)	136.2	214.5	96.5	517.6	1,093.1
Total Debt ($ Mil)	23.5	30.6	38.1	43.1	48.1
Total Cash ($ Mil)	38.3	41.9	81.0	277.6	376.5
Enterprise Value ($ Mil)	121.3	245.1	134.6	560.7	1,141.2
Valuation Ratios
P/S TTM	1.7	3.6	0.5	4.3	9.8
P/EBIT TTM	-2.2	-2.1	-0.8	-2.4	-5.9
P/E TTM	-2.1	-2.1	-0.4	-2.5	-6.1
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.9
P/E TTM (Sector)	-1.8	-1.5	-1.5	-1.3	-2.9

	9/18/25	2024	2023
Share Price CYE	$0.53	$1.02	$0.54
Market Cap CYE ($ Mil)	136.2	214.5	96.5
Total Debt ($ Mil)	23.5	30.6	38.1
Total Cash ($ Mil)	38.3	41.9	81.0
Enterprise Value ($ Mil)	121.3	245.1	134.6
Valuation Ratios
P/S TTM	1.7	3.6	0.5
P/EBIT TTM	-2.2	-2.1	-0.8
P/E TTM	-2.1	-2.1	-0.4
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-1.8	-1.5	-1.5

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
SGMO Return	86%	-52%	-58%	-83%	88%	-50%	-94%
Peers Return	43%	25%	6%	32%	20%	22%	267%
S&P 500 Return	16%	27%	-19%	24%	23%	12%	104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: PTGX, ABBV, AMGN, GILD, VRTX. See SGMO Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than Sangamo Therapeutics (SGMO)

	SGMO	Better Performance than SGMO
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	565.5%	MDGL (3422.0%), CYTK (2635.7%), ARWR (2816.2%), NAMS (762.1%), IBRX (4227.2%)
Rev Chg 3Y Avg	187.5%	BBIO (1225.0%), AXSM (699.5%), CYTK (824.6%), CRSP (380.7%), TGTX (539.4%)
Op Mgn LTM	-76.9%	ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM	-43.9%	ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM	-44.1%	ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield	-48.3%	ABBV (3.9%), AMGN (7.8%), GILD (7.3%), VRTX (3.7%), REGN (7.5%)

	SGMO	Better Performance than SGMO
Metric	Value	Sector (Health Care)
Rev Chg LTM	565.5%	MDGL (3422.0%), CYTK (2635.7%), ARWR (2816.2%), NAMS (762.1%), IBRX (4227.2%)
Rev Chg 3Y Avg	187.5%	BBIO (1225.0%), AXSM (699.5%), CYTK (824.6%), CRSP (380.7%), TGTX (539.4%)
Op Mgn LTM	-76.9%	LLY (43.0%), JNJ (24.5%), ABBV (23.5%), UNH (7.3%), ABT (17.4%)
CFO/Rev LTM	-43.9%	LLY (20.5%), JNJ (25.4%), ABBV (33.1%), UNH (6.8%), ABT (21.0%)
FCF/Rev LTM	-44.1%	LLY (-0.1%), JNJ (18.1%), ABBV (31.3%), UNH (6.0%), ABT (15.7%)
Total Yield	-48.3%	LLY (2.8%), JNJ (8.1%), ABBV (3.9%), UNH (9.4%), ABT (7.7%)

	SGMO	Better Performance than SGMO
Metric	Value	All Other Sectors
Rev Chg LTM	565.5%	QXO (3313.1%), CFFN (595.7%), IVR (1091.9%), HYLN (3559.4%), NREF (1066.4%)
Rev Chg 3Y Avg	187.5%	QXO (1115.2%), OTF (221.9%), VVV (262.7%), APLD (233.4%), ENVX (436.9%)
Op Mgn LTM	-76.9%	NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM	-43.9%	NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM	-44.1%	NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield	-48.3%	NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.9%)

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Sangamo Therapeutics (SGMO) Stock: 30% of days in last 3 months had 1% or greater fluctuation
2	Sangamo Therapeutics Market Price	Market Price
3	Sangamo Therapeutics vs. S&P500 Correlation	Correlation
4	Sangamo Therapeutics Price Volatility	Volatility
5	Day 5 of Gains Streak for Sangamo Therapeutics Stock with 42% Return (vs. -16% YTD) [7/14/2024]	Notification
6	Day 5 of Gains Streak for Sangamo Therapeutics Stock with 42% Return (vs. -16% YTD) [7/13/2024]	Notification
7	Day 6 of Loss Streak for Sangamo Therapeutics Stock with -31% Return (vs. -41% YTD) [7/2/2024]	Notification
8	Day 5 of Loss Streak for Sangamo Therapeutics Stock with -26% Return (vs. -36% YTD) [7/1/2024]	Notification
9	Day 5 of Loss Streak for Sangamo Therapeutics Stock with -24% Return (vs. -34% YTD) [6/30/2024]	Notification
10	Day 5 of Loss Streak for Sangamo Therapeutics Stock with -24% Return (vs. -34% YTD) [6/29/2024]	Notification
11	ARTICLES
12	Sangamo Therapeutics Stock Looks Attractive At $11		April 13th, 2021
13	What’s Next After The 15% Rally For Sangamo Therapeutics Stock Last Week?		March 22nd, 2021
14	Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?		March 4th, 2021

	Title
0	DASHBOARDS
1	Sangamo Therapeutics Stock Looks Attractive At $11
2	What’s Next After The 15% Rally For Sangamo Therapeutics Stock Last Week?
3	Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?
4	ARTICLES
5	Sangamo Therapeutics (SGMO) Stock: 30% of days in last 3 months had 1% or greater fluctuation
6	Sangamo Therapeutics Market Price
7	Sangamo Therapeutics vs. S&P500 Correlation
8	Sangamo Therapeutics Price Volatility
9	Day 5 of Gains Streak for Sangamo Therapeutics Stock with 42% Return (vs. -16% YTD) [7/14/2024]
10	Day 5 of Gains Streak for Sangamo Therapeutics Stock with 42% Return (vs. -16% YTD) [7/13/2024]
11	Day 6 of Loss Streak for Sangamo Therapeutics Stock with -31% Return (vs. -41% YTD) [7/2/2024]
12	Day 5 of Loss Streak for Sangamo Therapeutics Stock with -26% Return (vs. -36% YTD) [7/1/2024]
13	Day 5 of Loss Streak for Sangamo Therapeutics Stock with -24% Return (vs. -34% YTD) [6/30/2024]
14	Day 5 of Loss Streak for Sangamo Therapeutics Stock with -24% Return (vs. -34% YTD) [6/29/2024]

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3937.1%	307.9%
2	ATHA	Athira Pharma	890.3%	544.3%
3	SPRC	SciSparc	142.9%	1141.7%
4	ATCH	AtlasClear	87.4%	-83.1%
5	GV	Visionary	68.2%	14.8%
6	APLM	Apollomics	51.3%	89.1%
7	SQFT	Presidio Property Trust	46.3%	11.0%
8	CDT	CDT Equity	40.1%	-99.1%
9	EDUC	Educational Development	31.8%	9.1%
10	ILLR	Triller	29.8%	-37.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-83.5%	148.4%
2	CODX	Co-Diagnostics	-34.7%	-44.4%
3	BOXL	Boxlight	-34.5%	-13.5%
4	OPI	Office Properties Income Trust	-31.8%	-40.9%
5	BIAF	bioAffinity Technologies	-30.0%	-79.9%
6	ENVB	Enveric Biosciences	-29.3%	-88.0%
7	KAVL	Kaival Brands Innovations	-27.3%	-46.7%
8	AEI	Alset	-25.5%	211.8%
9	INBS	Intelligent Bio Solutions	-25.0%	0.7%
10	LVRO	Lavoro	-23.0%	-67.2%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3347.2%	307.9%
2	BDSX	Biodesix	1090.6%	-79.7%
3	CLSD	Clearside Biomedical	987.7%	-74.7%
4	ATHA	Athira Pharma	892.1%	544.3%
5	SDOT	Sadot	690.6%	-79.9%
6	ATCH	AtlasClear	684.9%	-83.1%
7	HSDT	Helius Medical Technologies	232.1%	-95.5%
8	CHEK	Check-Cap	222.2%	134.4%
9	APLM	Apollomics	197.8%	89.1%
10	SPRC	SciSparc	147.0%	1141.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-80.5%	148.4%
2	ATYR	aTyr Pharma	-80.4%	-71.7%
3	NAKA	Kindly MD	-70.2%
4	BNGO	Bionano Genomics	-64.0%	-89.8%
5	XAGE	Longevity Health	-57.6%	-86.1%
6	FAAS	DigiAsia	-55.4%	-88.0%
7	ASST	Strive	-54.5%	650.3%
8	VCIG	VCI Global	-51.0%	-98.9%
9	REX	REX American Resources	-50.7%	44.3%
10	RBNE	Robin Energy	-42.6%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	11931.7%	11931.7%
2	GIBO	GIBO	10714.0%
3	LNZA	LanzaTech Global	8455.2%	-86.3%
4	GTI	Graphjet Technology	3998.4%	-93.1%
5	GWAV	Greenwave Technology Solutions	3582.8%	-91.4%
6	QMMM	QMMM	3409.6%	8153.1%
7	ECDA	ECD Automotive Design	2715.2%	307.9%
8	OESX	Orion Energy Systems	1373.7%	14.2%
9	OP	OceanPal	1266.5%	-95.6%
10	BCTX	BriaCell Therapeutics	1032.4%	-89.8%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	CJET	Chijet Motor	-94.5%	-96.0%
2	STFS	Star Fashion Culture	-92.3%	-97.9%
3	ELPW	Elong Power	-91.1%	-76.9%
4	NXTT	Next Technology	-90.1%	-95.4%
5	EPIX	ESSA Pharma	-89.4%	-8.9%
6	NAKA	Kindly MD	-88.1%
7	BINI	Bollinger Innovations	-87.6%	-100.0%
8	JEM	707 Cayman	-87.4%	-98.2%
9	YAAS	Youxin Technology	-83.3%	-98.4%
10	NEON	Neonode	-82.5%	-51.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3937.1%	307.9%
2	ATHA	Athira Pharma	890.3%	544.3%
3	SPRC	SciSparc	142.9%	1141.7%
4	ATCH	AtlasClear	87.4%	-83.1%
5	GV	Visionary	68.2%	14.8%
6	APLM	Apollomics	51.3%	89.1%
7	SQFT	Presidio Property Trust	46.3%	11.0%
8	CDT	CDT Equity	40.1%	-99.1%
9	EDUC	Educational Development	31.8%	9.1%
10	ILLR	Triller	29.8%	-37.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-83.5%	148.4%
2	CODX	Co-Diagnostics	-34.7%	-44.4%
3	BOXL	Boxlight	-34.5%	-13.5%
4	OPI	Office Properties Income Trust	-31.8%	-40.9%
5	BIAF	bioAffinity Technologies	-30.0%	-79.9%
6	ENVB	Enveric Biosciences	-29.3%	-88.0%
7	KAVL	Kaival Brands Innovations	-27.3%	-46.7%
8	AEI	Alset	-25.5%	211.8%
9	INBS	Intelligent Bio Solutions	-25.0%	0.7%
10	LVRO	Lavoro	-23.0%	-67.2%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	ECDA	ECD Automotive Design	3347.2%	307.9%
2	BDSX	Biodesix	1090.6%	-79.7%
3	CLSD	Clearside Biomedical	987.7%	-74.7%
4	ATHA	Athira Pharma	892.1%	544.3%
5	SDOT	Sadot	690.6%	-79.9%
6	ATCH	AtlasClear	684.9%	-83.1%
7	HSDT	Helius Medical Technologies	232.1%	-95.5%
8	CHEK	Check-Cap	222.2%	134.4%
9	APLM	Apollomics	197.8%	89.1%
10	SPRC	SciSparc	147.0%	1141.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	CURX	Curanex Pharmaceuticals	-80.5%	148.4%
2	ATYR	aTyr Pharma	-80.4%	-71.7%
3	NAKA	Kindly MD	-70.2%
4	BNGO	Bionano Genomics	-64.0%	-89.8%
5	XAGE	Longevity Health	-57.6%	-86.1%
6	FAAS	DigiAsia	-55.4%	-88.0%
7	ASST	Strive	-54.5%	650.3%
8	VCIG	VCI Global	-51.0%	-98.9%
9	REX	REX American Resources	-50.7%	44.3%
10	RBNE	Robin Energy	-42.6%

Peer Comparisons for Sangamo Therapeutics

Financials

	SGMO	PTGX	ABBV	AMGN	GILD	VRTX	Median
Name	Sangamo .	Protagon.	AbbVie	Amgen	Gilead S.	Vertex P.
Mkt Price	0.51	59.22	220.81	274.71	112.26	387.15	166.53
Mkt Cap	0.1	3.8	390.4	147.8	139.8	99.4	119.6
Rev LTM	82	209	58,328	34,917	28,862	11,419	20,140
Op Inc LTM	-63	24	13,695	8,192	10,797	-199	4,108
FCF LTM	-36	37	18,239	10,605	9,369	3,500	6,434
FCF 3Y Avg	-160	50	20,273	8,590	8,397	1,984	5,191
CFO LTM	-36	40	19,283	12,013	9,868	3,846	6,857
CFO 3Y Avg	-149	51	21,154	9,753	8,949	2,324	5,636

Growth & Margins

	SGMO	PTGX	ABBV	AMGN	GILD	VRTX	Median
Name	Sangamo .	Protagon.	AbbVie	Amgen	Gilead S.	Vertex P.
Rev Chg LTM	565.5%	-34.5%	6.1%	12.9%	3.8%	10.5%	8.3%
Rev Chg 3Y Avg	187.5%	-	0.6%	10.0%	1.6%	11.0%	10.0%
Rev Chg Q	5,042.1%	33.1%	6.6%	9.4%	1.8%	12.1%	10.7%
QoQ Delta Rev Chg LTM	28.2%	0.7%	1.7%	2.3%	0.4%	2.9%	2.0%
Op Mgn LTM	-76.9%	11.5%	23.5%	23.5%	37.4%	-1.7%	17.5%
Op Mgn 3Y Avg	-602.4%	-	27.2%	26.4%	39.2%	26.5%	26.5%
QoQ Delta Op Mgn LTM	50.0%	-1.6%	1.0%	1.6%	-0.0%	2.0%	1.3%
CFO/Rev LTM	-43.9%	18.9%	33.1%	34.4%	34.2%	33.7%	33.4%
CFO/Rev 3Y Avg	-521.6%	-	37.5%	32.0%	31.9%	22.5%	31.9%
FCF/Rev LTM	-44.1%	17.7%	31.3%	30.4%	32.5%	30.6%	30.5%
FCF/Rev 3Y Avg	-540.6%	-	36.0%	28.2%	30.0%	19.2%	28.2%

Valuation

	SGMO	PTGX	ABBV	AMGN	GILD	VRTX	Median
Name	Sangamo .	Protagon.	AbbVie	Amgen	Gilead S.	Vertex P.
Mkt Cap	0.1	3.8	390.4	147.8	139.8	99.4	119.6
P/S	1.6	18.0	6.7	4.2	4.8	8.7	5.8
P/EBIT	-2.1	156.9	66.3	14.3	17.0	22.6	19.8
P/E	-2.1	72.3	103.7	22.3	22.1	27.3	24.8
P/CFO	-3.7	95.1	20.2	12.3	14.2	25.8	17.2
Total Yield	-48.3%	1.4%	3.9%	7.8%	7.3%	3.7%	3.8%
Dividend Yield	0.0%	0.0%	2.9%	3.4%	2.8%	0.0%	1.4%
FCF Yield 3Y Avg	-129.2%	1.5%	7.3%	6.2%	8.0%	2.1%	4.1%
D/E	0.2	0.0	0.2	0.4	0.2	0.0	0.2
Net D/E	-0.1	-0.1	0.2	0.3	0.1	-0.0	0.0

Returns

	SGMO	PTGX	ABBV	AMGN	GILD	VRTX	Median
Name	Sangamo .	Protagon.	AbbVie	Amgen	Gilead S.	Vertex P.
1M Rtn	-13.0%	5.4%	6.9%	-6.1%	-4.2%	-0.7%	-2.4%
3M Rtn	4.4%	9.8%	20.1%	-4.4%	4.7%	-13.7%	4.5%
6M Rtn	-41.0%	9.0%	5.9%	-11.5%	5.9%	-24.5%	-2.8%
12M Rtn	-38.5%	31.9%	18.2%	-14.7%	39.2%	-19.6%	1.8%
3Y Rtn	-90.2%	608.4%	71.6%	30.8%	90.5%	33.6%	52.6%
1M Excs Rtn	-15.3%	3.0%	4.5%	-8.5%	-6.5%	-3.0%	-4.8%
3M Excs Rtn	-4.2%	-3.1%	9.8%	-14.8%	-5.7%	-22.7%	-4.9%
6M Excs Rtn	-57.0%	-8.9%	-12.4%	-29.9%	-14.3%	-42.0%	-22.1%
12M Excs Rtn	-56.9%	8.6%	0.4%	-31.9%	22.3%	-37.6%	-15.7%
3Y Excs Rtn	-151.7%	497.4%	13.2%	-33.4%	25.2%	-28.7%	-7.7%

Comparison Analyses

	Title
0	Sangamo Therapeutics vs bluebird bio: Industry Peers; Which Stock Is A Better Bet?
1	Sangamo Therapeutics vs Shenandoah Telecommunications Co: Similar Market Cap; Which Stock Is A Better Bet?
2	Sangamo Therapeutics vs Arch Coal: Similar Market Cap; Which Stock Is A Better Bet?
3	Sangamo Therapeutics vs Steelcase: Similar Market Cap; Which Stock Is A Better Bet?
4	Sangamo Therapeutics vs Clovis Oncology: Similar Revenue; Which Stock Is A Better Bet?
5	Sangamo Therapeutics vs Mitek Systems: Similar Revenue; Which Stock Is A Better Bet?

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/7/2025	3/17/2025	3/13/2024	2/23/2023	2/24/2022	2/24/2021	2/28/2020
Key Financials
Total Revenue	82	58	176	111	111	118	102
EBITDA	-55	-89	-97	-181	-166	-116	-96
Operating Income	-63	-98	-119	-201	-183	-130	-105
Net Income	-63	-98	-258	-192	-178	-121	-95
EPS	-0.28	-0.49	-1.48	-1.25	-1.23	-0.90	-0.85
Growth Rates
Total Revenue Growth	565.5%	-67.2%	58.3%	0.5%	-6.3%	15.4%	21.3%
EBITDA Growth	71.3%	8.0%	46.4%	-9.1%	-42.6%	-21.6%	-27.8%
Operating Income Growth	69.6%	17.3%	40.9%	-9.8%	-41.5%	-23.2%	-36.3%
Net Income Growth	74.6%	62.0%	-34.1%	-7.8%	-47.3%	-27.1%	-39.3%
Margins
EBITDA Margin	-67.0%	-154.1%	-54.9%	-162.4%	-149.7%	-98.3%	-93.3%
Operating Income Margin	-76.9%	-170.3%	-67.5%	-180.8%	-165.6%	-109.6%	-102.7%
Net Income Margin	-77.5%	-169.4%	-146.3%	-172.8%	-161.1%	-102.4%	-92.9%
Cash & Debt
Total Cash	38	42	81	278	377	641	362
Total Debt	23	31	38	43	48	42	44
Net Debt / (Cash)	-15	-11	-43	-235	-328	-599	-318
Cash Flows
Net Cash from Operations	-36	-67	-225	-224	-233	170	-144
Free Cash from Operations	-36	-67	-246	-244	-257	155	-165
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/7/2025	5/12/2025	3/17/2025	11/12/2024	8/6/2024	5/9/2024	3/13/2024	11/1/2023	8/8/2023	5/8/2023	2/23/2023	11/3/2022
Key Financials Quarterly
Total Revenue	18	6	8	49	0	0	2	9	7	158	27	26
Ebitda	-16	-28	-24	13	-33	-45	-59	-54	-66	82	-50	-50
Operating Income	-18	-30	-26	11	-36	-47	-62	-62	-72	77	-55	-55
Net Income	-20	-31	-23	11	-36	-49	-60	-104	-115	21	-52	-53
EPS	-0.08	-0.14	-0.11	0.05	-0.18	-0.27	-0.34	-0.59	-0.66	0.13	-0.32	-0.34
Key Financials TTM
Total Revenue TTM	82	64	58	52	12	19	176	201	218	241	111	112
Ebitda TTM	-55	-72	-89	-124	-191	-224	-97	-88	-84	-58	-181	-166
Operating Income TTM	-63	-81	-98	-134	-206	-243	-119	-113	-106	-79	-201	-186
Net Income TTM	-63	-79	-98	-135	-250	-328	-258	-250	-199	-127	-192	-178
Growth Rates Quarterly
Total Revenue Growth	5042.1%	1238.3%	269.8%	425.8%	-94.8%	-99.7%	-92.5%	-64.5%	-76.7%	459.5%	-2.7%	-7.4%
EBITDA Growth	52.1%	38.0%	59.4%	123.5%	49.5%	-154.3%	-17.6%	-9.0%	-62.1%	303.8%	-42.6%	-13.4%
Operating Income Growth	50.3%	37.2%	57.9%	117.3%	50.3%	-161.6%	-11.5%	-12.2%	-57.9%	269.3%	-38.8%	-13.3%
Net Income Growth	44.7%	37.7%	61.2%	110.2%	68.4%	-332.3%	-16.0%	-96.0%	-165.2%	148.1%	-38.6%	-11.5%
Margins Quarterly
EBITDA Margin	-87.2%	-430.4%	-315.9%	25.8%	-9364.9%	-9283.0%	-2877.3%	-576.6%	-966.2%	52.0%	-183.4%	-187.9%
Operating Income Margin	-97.5%	-460.3%	-344.2%	21.5%	-10087.6%	-9808.1%	-3024.6%	-655.6%	-1056.7%	48.5%	-203.4%	-207.5%
Net Income Margin	-109.2%	-475.3%	-309.8%	21.6%	-10148.3%	-10205.6%	-2952.7%	-1108.4%	-1675.3%	13.4%	-190.9%	-200.9%
Cash & Debt
Total Cash	38	25	42	39	28	54	81	132	143	205	278	314
Total Debt	23	25	31	28	29	31	38	35	36	38	43	40
Net Debt / (Cash)	-15	-0	-11	-11	1	-24	-43	-97	-107	-168	-235	-274
Cash Flows Quarterly
FCF from Operations	-18	-26	-3	12	-27	-49	-51	-47	-61	-66	-57	-54
Cash Flows TTM
FCF from Operations TTM	-36	-45	-67	-114	-173	-207	-225	-231	-238	-231	-224	-219
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-4.6%	-7.7%	-6.7%	2.8%	-9.5%	-12.7%	-17.0%	-17.8%	-20.0%	23.4%	-18.3%	-19.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-4.0%	-5.2%	-6.5%	-8.9%	-13.6%	-16.1%	-8.1%	-8.0%	-7.5%	-6.1%	-16.6%	-16.4%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	176	111	111	118	102
Total	176	111	111	118	102

Net Income by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	-258
Total	-258

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$0.51
Market Cap ($ Bil)	0.1
First Trading Date	04/06/2000
Distance from 52W High	-82.1%
	50 Days	200 Days
DMA Price	$0.53	$0.91
DMA Trend	down	up
Distance from DMA	-3.2%	-43.6%
	3M	1YR
Volatility	88.5%	134.1%
Downside Capture	313.11	251.52
Upside Capture	169.79	162.30
Correlation (SPY)	17.4%	22.7%

SGMO Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.92	1.86	2.58	0.93	1.64	1.54
Up Beta	1.12	2.75	3.20	1.21	1.74	1.46
Down Beta	-3.49	-1.77	-0.09	-0.20	0.76	0.75
Up Capture	156%	189%	288%	53%	297%	331%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	9	17	27	60	115	327
Down Capture	270%	318%	318%	160%	156%	109%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	12	24	34	64	127	406

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8292025
Short Interest: Shares Quantity	14,978,395
Short Interest: % Change Since 8152025	-6.1%
Average Daily Volume	4,264,819
Days-to-Cover Short Interest	3.51
Basic Shares Quantity	256,950,000
Short % of Basic Shares	5.8%

Returns Analyses

	Title
0	SGMO Lost 14% In A Month. Do You Buy Or Wait?
1	Sangamo Therapeutics Stock Return Comparison
2	Sangamo Therapeutics Total Shareholder Return (TSR): -58.1% in 2022 and -27.9% 3-yr returns (above peer average)
3	Sangamo Therapeutics (SGMO) Stock Return: AI Predicts SGMO Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/7/2025	-5.3%	11.9%	8.8%
3/17/2025	-16.2%	-13.9%	-26.9%
11/12/2024	-10.0%	-27.7%	-29.5%
8/6/2024	-13.5%	-1.5%	-24.1%
3/13/2024	-8.8%	-10.6%	-36.7%
11/1/2023	-22.1%	-35.7%	-23.1%
8/8/2023	-7.9%	-11.4%	-16.5%
2/22/2023	0.3%	1.4%	-41.6%
...
SUMMARY STATS
# Positive	8	9	6
# Negative	12	11	14
Median Positive	5.7%	10.5%	12.4%
Median Negative	-9.4%	-10.6%	-16.0%
Max Positive	28.0%	28.0%	23.3%
Max Negative	-22.1%	-35.7%	-41.6%

	Forward Returns
8/7/2025	-5.3%	11.9%	8.8%
3/17/2025	-16.2%	-13.9%	-26.9%
11/12/2024	-10.0%	-27.7%	-29.5%
8/6/2024	-13.5%	-1.5%	-24.1%
3/13/2024	-8.8%	-10.6%	-36.7%
11/1/2023	-22.1%	-35.7%	-23.1%
8/8/2023	-7.9%	-11.4%	-16.5%
2/22/2023	0.3%	1.4%	-41.6%
11/3/2022	-12.8%	-3.9%	-14.7%
8/4/2022	9.0%	22.0%	15.9%
5/5/2022	-3.7%	-12.1%	-14.0%
2/24/2022	3.3%	-1.6%	0.7%
11/4/2021	19.1%	10.5%	-11.4%
8/5/2021	-2.1%	2.4%	1.1%
2/24/2021	-10.6%	-10.5%	-2.0%
11/4/2020	1.4%	-5.1%	-15.5%
8/5/2020	1.9%	1.6%	-12.3%
5/11/2020	8.1%	15.5%	22.1%
2/28/2020	28.0%	28.0%	-4.9%
11/6/2019	-1.3%	2.4%	23.3%
SUMMARY STATS
# Positive	8	9	6
# Negative	12	11	14
Median Positive	5.7%	10.5%	12.4%
Median Negative	-9.4%	-10.6%	-16.0%
Max Positive	28.0%	28.0%	23.3%
Max Negative	-22.1%	-35.7%	-41.6%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8072025	10-Q 6/30/2025
3312025	5122025	10-Q 3/31/2025
12312024	3172025	10-K 12/31/2024
9302024	11122024	10-Q 9/30/2024
6302024	8062024	10-Q 6/30/2024
3312024	5092024	10-Q 3/31/2024
12312023	3132024	10-K 12/31/2023
9302023	11012023	10-Q 9/30/2023
6302023	8082023	10-Q 6/30/2023
3312023	5082023	10-Q 3/31/2023
12312022	2232023	10-K 12/31/2022
9302022	11032022	10-Q 9/30/2022
6302022	8042022	10-Q 6/30/2022
3312022	5052022	10-Q 3/31/2022
12312021	2242022	10-K 12/31/2021
9302021	11042021	10-Q 9/30/2021

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Sangamo Therapeutics (SGMO)

Market Price (9/18/2025): $0.53 | Market Cap: $136.2 MilSector: Health Care | Industry: Biotechnology

Sangamo Therapeutics (SGMO)

Market Price (9/18/2025): $0.53Market Cap: $136.2 MilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Sangamo Therapeutics (SGMO)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Sangamo Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/18/2025): $0.53 | Market Cap: $136.2 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (9/18/2025): $0.53
Market Cap: $136.2 Mil
Sector: Health Care
Industry: Biotechnology